Drug-loaded table-top transdermal nursing system

Abstract

The present application relates to a kind of microneedle transdermal drug delivery technology, in particular, it relates to a kind of drug-loaded table transdermal nursing system.The drug-loaded table transdermal nursing system includes penetration device, penetration device includes penetration unit, and the penetration unit has substrate and the penetration micro-unit formed on substrate;It further includes delivery device;Delivery device includes delivery unit, and the delivery unit has drug-loading platform, and drug-loading surface of drug-loading platform is provided with drug coating, and drug coating has water-soluble and contains active ingredient;Delivery device can be delivered active ingredient by the reciprocating touch of the skin of specific area multiple times, and when the skin of specific area is touched each time, drug coating partially dissolves, and when the number of touch reaches specific number, drug coating completely dissolves.The nursing system is simple and convenient to operate, can realize the accurate, stable control of drug dosage, can be implemented uniform nursing to specific skin area, and can be suspended or discontinued at any time.

Description

Technical Field

[0001] This invention relates to a microneedle transdermal drug delivery technology, and more particularly, to a drug-loaded desktop transdermal care system. Background Technology

[0002] In the field of transdermal drug delivery technology, chemical transdermal delivery methods have long dominated. In daily life, applying moisturizer to the skin is a common transdermal drug delivery technique; another example is the use of ointments in the medical field. However, this method often relies on chemical penetration enhancers to improve the transdermal absorption efficiency of drugs. These chemical penetration enhancers often cause skin discomfort, such as itching, redness, swelling, and allergic reactions, significantly impacting the patient's experience. In light of this, physical transdermal drug delivery technology has emerged. Among physical transdermal drug delivery technologies, microneedle transdermal drug delivery technology has many advantages.

[0003] Microneedle transdermal products are made from metals, monocrystalline silicon, polymers, or other suitable materials, and have a substrate and an array of microneedles formed on the substrate. Microneedle transdermal products act on the skin surface through the microneedle array, overcoming the skin's surface barrier layer and forming open channels, allowing for rapid and efficient transdermal absorption of active ingredients. Among physical transdermal drug delivery technologies, there are various transdermal microneedle products. Among them, the microneedle array on nanochips achieves nanometer-level precision and has advantages such as being non-invasive, painless, safe, and highly effective, gaining favor from experts both domestically and internationally.

[0004] However, despite the numerous advantages of microneedle transdermal drug delivery technology, current implementation methods have several shortcomings. Existing methods typically involve applying active ingredients or skincare products to the skin surface before using transdermal microneedles for puncture and drainage. This method faces the following problems in practice: First, it is difficult to accurately determine whether the active ingredients applied to the skin surface have been completely absorbed, making it challenging to precisely control the dosage. Second, active ingredient residue on the skin surface is common, not only wasting the active ingredients but also potentially causing unnecessary skin irritation. Third, the inability to clearly and conveniently track the drug delivery progress makes it difficult for patients to monitor the treatment process in real time. Fourth, the lack of flexible control methods during drug delivery makes it impossible to accommodate the need to pause or adjust the delivery rate midway.

[0005] Furthermore, and more importantly, many active ingredients and substances exhibit poor stability in liquid or paste forms, and long-term storage can easily lead to reduced activity or inactivation. This further limits the application scope and promotion of microneedle transdermal drug delivery technology. Particularly in the medical field, active ingredients such as insulin, smegglutinin, conospirin, tranexamic acid, and hexapeptides, due to their specific storage requirements, are difficult to integrate with current microneedle transdermal drug delivery methods, forcing patients to continue to endure the pain and inconvenience of traditional injection treatments.

[0006] In the medical field, transdermal microneedle drug delivery technology has led to the development of soluble microneedles. These microneedles are made entirely of soluble materials, designed to detach from the substrate and remain in the skin after a single puncture. However, in practice, instability issues frequently arise, such as the needle failing to detach effectively, insufficient structural strength preventing effective skin penetration, and easy breakage. Even if the needle structure is sufficiently strong, after the first or a few punctures, the material's solubility causes the needle to gradually dissolve, leading to blunting of the tip and loss of puncture capability. Therefore, traditional soluble microneedles are limited to targeted drug delivery treatment in extremely small areas of the skin.

[0007] In summary, current microneedle transdermal drug delivery technology suffers from drawbacks such as uncertain dosage, drug waste, difficulty in controlling the drug delivery process, difficulty in storing active substances, and inability to deliver drugs evenly. These drawbacks hinder the development of microneedle transdermal drug delivery technology in medical and aesthetic fields and limit the technological progress of my country's next generation of painless medical care. Summary of the Invention

[0008] To address the technical shortcomings of existing transdermal drug delivery methods, such as uncertain dosage, drug waste, difficulty in controlling the drug delivery process, difficulty in storing active substances, and inability to deliver drugs evenly, this invention provides a drug-loaded benchtop transdermal care system. This system includes a penetration-enhancing device comprising a penetration-enhancing unit having a substrate and penetration-enhancing micro-units formed on the substrate. The penetration-enhancing device weakens the skin barrier by repeatedly touching a specific area of ​​skin; it also moistens the skin in the weakened area. Furthermore, it includes a delivery device comprising a delivery unit having a drug-loading platform. A drug coating, water-soluble and containing an active ingredient, is disposed on the drug-loading surface of the platform. The delivery device delivers the active ingredient by repeatedly touching the specific area of ​​skin. Each time the skin in the specific area is touched, the drug coating partially dissolves, and after a certain number of touches, the drug coating completely dissolves.

[0009] The above technical solutions will be further explained.

[0010] The permeation-enhancing unit refers to the transdermal microneedle product in this field of microneedle transdermal drug delivery technology. When the permeation-enhancing unit comes into contact with the skin, it punctures the skin, weakening the barrier protection of the stratum corneum and improving the transdermal absorption efficiency of the active ingredient. In this technical solution, the permeation-enhancing unit includes a substrate and permeation-enhancing microunits formed on the substrate. One optional processing method involves processing the substrate surface using a 3D etching process to directly form the permeation-enhancing microunits on the substrate.

[0011] Permeation-enhancing or delivery devices: Permeation-enhancing or delivery devices can be powered in various ways. They can be manually driven or electrically driven. Electrically driven devices can be mechanical transmission devices driven by electric motors or electromagnetically driven mechanical transmission devices, etc.

[0012] Infiltration facilitator unit: In addition to the substrate and infiltration facilitator micro-units, the infiltration facilitator unit may also include common components such as fixing components, supporting components, and connectors. The infiltration facilitator unit can be directly assembled onto the infiltration facilitator device, or assembled onto the infiltration facilitator device through these common components. Furthermore, the fixing components and supporting components make the assembly of the infiltration facilitator unit and the infiltration facilitator device more stable and reliable.

[0013] Delivery Unit: In addition to the drug delivery platform, the delivery unit may also include common components such as fixing components, supporting components, and connectors. The delivery unit can be directly assembled onto the delivery device, or assembled onto the delivery device through these common components. Furthermore, the fixing components and supporting components make the assembly of the delivery unit and the delivery device more stable and reliable.

[0014] Drug Coating: The drug coating is a solid substance attached to the drug delivery platform of the delivery unit. The drug coating is water-soluble. Each time the delivery unit touches the skin surface, the drug coating comes into contact with the water on the skin and partially dissolves. The drug then penetrates deeper into the skin along with the water, and the active ingredient is absorbed by the skin. After a certain number of contacts, the drug coating is completely dissolved and absorbed.

[0015] Moistening treatment: In this technical solution, moistening treatment can take many specific forms, such as cleaning the skin with clean water, applying a wet wipe to the skin, spraying water on the skin, and atomizing the skin surface.

[0016] The inventive concept of this invention is as follows: This technical solution uses a penetration-enhancing device to care for the skin, weakening the skin's stratum corneum barrier and giving the skin a stronger transdermal absorption capacity. By moisturizing the skin, the skin microenvironment is altered, making the skin tissue more conducive to the dissolution and absorption of active ingredients. Based on this, a delivery device is used to care for specific areas of the skin. In this technical solution, active substances and other effective ingredients are stored in solid form on the delivery device, maintaining their activity for a long time and facilitating transportation and storage. The core of this delivery device—the drug-carrying platform—is designed with a unique drug coating structure, enabling a micro-drug coating to rapidly dissolve in the skin's surface moisture upon each skin contact, allowing the carried active ingredients to efficiently adhere and penetrate deep into the skin. Especially when using a high-precision electrically driven mechanical transmission system, the delivery unit can repeatedly contact the skin at a constant and high-frequency rate, with precisely controllable contact duration. Therefore, the amount of drug coating and active ingredients dissolved into the skin each time is fixed, achieving precise quantification of the amount of drug coating and active ingredients penetrating into the skin.

[0017] The beneficial effects of this invention are:

[0018] This technical solution utilizes a solid form to store the active ingredients. This solid form not only extends the shelf life of the active ingredients but also greatly facilitates transportation and long-term storage. During use, the active ingredients are cleverly placed within a drug coating, ensuring rapid dissolution and efficient absorption upon contact with skin moisture. This design shortens the exposure time of the active ingredients, effectively maintaining their activity. In practical operation, this care system can provide uniform care to specific areas of skin. Especially when using a high-precision, electrically driven mechanical transmission system, the drug dosage can be released slowly and controllably, with precise dosage and stable control. This enables precise, targeted, layered, and positional care, greatly improving the accuracy and reliability of treatment or maintenance processes.

[0019] From a user operation perspective, this care system is simple to use. Users only need to lightly touch the treatment area with the delivery device, without needing to worry about the application or dripping of active ingredients, greatly reducing the difficulty of operation. Furthermore, the system offers high operational flexibility and interruptibility, allowing users or caregivers to pause or stop the treatment process at any time according to medical guidance or personalized maintenance plans. After the treatment is paused, the active ingredients remaining in the drug coating remain active, preventing waste. Simultaneously, because the residual active ingredients can immediately separate from the skin, no new active ingredients will come into contact with or be absorbed by the skin after the treatment is paused. This feature is particularly important in case of emergencies such as drug allergies. Therefore, this technical solution also ensures the flexibility to adjust the treatment process.

[0020] In summary, this nursing system, through its intelligent and precise operational design, enables the slow and controlled release of active ingredients, significantly reducing drug waste and greatly improving resource utilization efficiency. Furthermore, the system simplifies user operation, offering high flexibility and interruptibility, thus broadening the prospects for the development of microneedle transdermal drug delivery technology in medical and aesthetic fields.

[0021] In a preferred embodiment, the specific region includes at least one of the following: head, face, periorbital area, neck, and hand.

[0022] In a preferred embodiment, the permeation-enhancing microunit is formed from at least one of monocrystalline silicon, ceramics, and polymer materials.

[0023] In a preferred embodiment, the end of the permeation-enhancing micro-unit is conical, pyramidal, or blade-shaped.

[0024] In a preferred embodiment, the length of the permeation-enhancing micro-unit is no greater than 3000 micrometers.

[0025] In a preferred embodiment, the end diameter of the permeation-enhancing microunit is no greater than 200 nanometers. This embodiment achieves nanoscale end-level permeation enhancement, enabling painless and non-invasive high-efficiency permeation enhancement.

[0026] In a preferred embodiment, the active ingredient includes at least one of finasteride, minoxidil, GLP-1, insulin, semaglutide, conospirin, tranexamic acid, hexapeptide, salicylic acid, L-ascorbic acid, retinoic acid, and botulinum toxin. In this preferred embodiment, this drug-loaded desktop transdermal care system can care for the scalp, improve the absorption efficiency of the active ingredients, stimulate hair follicles and hair regeneration, and provide a more convenient and comfortable treatment experience for hair loss patients.

[0027] In a preferred embodiment, the content of finasteride is not less than 0.01% and not more than 3%.

[0028] In the preferred embodiment, the content of minoxidil is not less than 0.01% and not more than 5%.

[0029] In a preferred embodiment, the drug-carrying surface is planar. This embodiment provides a delivery unit with a planar drug-carrying surface. The drug coating dissolves upon contact with moisture on the skin surface, and the active ingredient carried thereon is absorbed by the skin.

[0030] In a preferred embodiment, the drug-carrying surface has delivery micro-units, and the drug coating covers both the drug-carrying surface and the delivery micro-units, or the drug coating covers only the delivery micro-units. In this embodiment, the delivery micro-units can be micro-protrusions, microneedles, or microblades. This embodiment provides a delivery unit with protruding structures on the drug-carrying surface. The drug coating covering the delivery micro-units can penetrate deeper into the skin; the drug coating dissolves upon contact with moisture in the skin, allowing the active ingredient to be efficiently absorbed by the skin.

[0031] In a further preferred embodiment, the penetration-enhancing unit is used instead of the delivery unit, the drug-carrying surface is formed on the surface of the substrate, the penetration-enhancing microunit replaces the delivery microunit, and the drug coating covers the drug-carrying surface and the penetration-enhancing microunit, or the drug coating only covers the penetration-enhancing microunit; the skin in a specific area is moistened; the penetration-enhancing device is used to drive the penetration-enhancing unit to repeatedly touch the skin in the specific area; each time the skin in the specific area is touched, the drug coating partially dissolves, and when the number of touches reaches a certain number, the drug coating completely dissolves.

[0032] In this preferred technical solution, the permeation-enhancing microunit and the delivery microunit are integrated into one. This preferred technical solution differs significantly from traditional soluble microneedles in terms of product structure, usage, and functional effects, which will be analyzed in detail below.

[0033] Traditional soluble microneedles are made of soluble materials. They are used by detaching from the base and remaining in the skin after a single puncture. These soluble microneedles are for single-use only, limiting their application to targeted drug delivery in very small areas of the skin. This type of soluble microneedle suffers from instability, including difficulty in effective detachment, insufficient structural strength to effectively puncture the skin, and easy breakage. It's important to note that even if the needle structure is strong enough to effectively puncture the skin, the traditional soluble microneedle will gradually dissolve after the first or a few punctures, leading to blunting of the tip. Therefore, traditional soluble microneedles, due to their structural strength and application scenarios, cannot be used for numerous repeated punctures, limiting their application to targeted drug delivery in very small areas of the skin.

[0034] In this preferred technical solution, the penetration-enhancing microunit uses a solid microneedle body with sufficient structural strength to efficiently and stably puncture the skin. While the penetration-enhancing microunit contacts the skin and weakens the skin barrier, the drug coating directly contacts the deep layers of the skin. The drug coating comes into contact with and dissolves in the skin's moisture, allowing the carried active ingredients to be efficiently absorbed. By controlling the dissolution rate of the drug coating, it is ensured that it only completely dissolves after a specific number of punctures, enabling large-scale, repeated skin punctures. Throughout the treatment process, the drug coating slowly dissolves and releases, achieving comprehensive and uniform skin care. This preferred technical solution further simplifies the operation of the treatment system, making it convenient for users.

[0035] In a further preferred embodiment, the end of the permeation-enhancing microunit has multiple tips, which are clustered together, and the drug coating is arranged in the gaps between the tips. In this embodiment, the multiple tips at the end of the permeation-enhancing microunit significantly increase the adhesion area of ​​the coating; simultaneously, the clustered tips form a drug storage space, which greatly increases the drug storage capacity of the permeation-enhancing microunit, thus facilitating the delivery of large doses of drug.

[0036] In a preferred embodiment, the specific number of touches is no less than 100 and no more than 50,000. This preferred embodiment allows for precise and quantitative adjustment of the dissolution rate of the drug coating by adjusting the number of touches required for complete dissolution. For example, eye area skin care typically takes less than 30 seconds, ensuring the drug coating dissolves completely after 1000 touches. Using a vibration frequency of 2000 times per minute for the delivery device allows the user to complete eye area care within half a minute, while the active ingredients in the drug coating are evenly absorbed by the skin around the eyes. Alternatively, the vibration frequency of the delivery device can typically be between 1000 and 5000 times per minute. Depending on the specific number of touches, the delivery device can be used for tens of seconds to tens of minutes to complete skin care for different areas such as the eye area, face, and scalp. Attached Figure Description

[0037] Figure 1 This is a flowchart of one embodiment of the drug-loaded desktop transdermal care system of the present invention.

[0038] Figure 2 This is a schematic diagram of the permeation-enhancing device in Embodiment 1 of the drug-loaded tabletop transdermal care system of the present invention.

[0039] Figure 3 This is a schematic diagram of the permeation enhancement unit in Embodiment 1 of the drug-loaded tabletop transdermal care system of the present invention.

[0040] Figure 4 This is a schematic diagram of the delivery unit in Embodiment 1 of the drug-loaded tabletop transdermal care system of the present invention.

[0041] Figure 5 This is a schematic diagram of the delivery unit in Embodiment 2 of the drug-loaded tabletop transdermal care system of the present invention.

[0042] Figure 6 This is a flowchart of Embodiment 3 of the drug-loaded desktop transdermal care system of the present invention.

[0043] Figure 7 This is a schematic diagram of the permeation enhancement unit in Embodiment 3 of the drug-loaded transdermal care system of the present invention.

[0044] Figure 8 This is a schematic diagram of the permeation enhancement unit in Embodiment 4 of the drug-loaded tabletop transdermal care system of the present invention.

[0045] Figure 9 This is a schematic diagram of the permeation enhancement unit in Embodiment 5 of the drug-loaded transdermal care system of the present invention.

[0046] List of reference numerals in the attached diagram:

[0047] 1. Permeation enhancement device; 10. Drive rod; 11. Permeation enhancement unit; 12. Connector; 111. Substrate; 112. Permeation enhancement micro-unit; 113. Tip; 21. Delivery unit; 211. Drug loading platform; 210. Drug loading surface; 212. Delivery micro-unit; 22. Drug coating. Detailed Implementation

[0048] The present technical solution will be further explained and illustrated below through some embodiments. It should be noted that the following embodiments are only used to make the inventive concept and design idea of ​​the present technical solution clearer and are not intended to limit the scope of protection of the present invention. It is readily understood that other embodiments completed under the guidance of the inventive concept of the present technical solution should also fall within the scope of protection of the present invention.

[0049] To address the technical shortcomings of existing transdermal drug delivery systems, such as uncertain dosage, drug waste, and difficulty in controlling the drug delivery process, this invention provides a drug-loaded transdermal care system. The operation of this drug-loaded transdermal care system includes the following steps: Step s1: Repeatedly touching a specific area of ​​skin with a penetration-enhancing device 1 to weaken the skin barrier; the penetration-enhancing device 1 includes a penetration-enhancing unit 11, which has a substrate 111 and penetration-enhancing micro-units 112 formed on the substrate 111; Step s2: Moistening the specific area of ​​skin where the barrier has been weakened; Step s3: Repeatedly touching the specific area of ​​skin with a delivery device to deliver the active ingredient; the delivery device includes a delivery unit 21, which has a drug-loading platform 211. A drug coating 22 is disposed on the drug-loading surface 210 of the drug-loading platform 211. The drug coating 22 is water-soluble and contains the active ingredient; each time the specific area of ​​skin is touched, the drug coating 22 partially dissolves, and after a certain number of touches, the drug coating 22 completely dissolves.

[0050] In this technical solution, the specific area can be the head, face, around the eyes, neck, hands, or other suitable parts. It is easy to understand that steps s1 and s2 above can be performed simultaneously, or the order of steps s1 and s2 can be interchanged.

[0051] In this technical solution, the penetration-enhancing device 1 includes a drive motor, a power supply, a switch, a reciprocating transmission mechanism, and a transmission rod 10, wherein the transmission rod 10 is used for assembly and connection with the penetration-enhancing unit 11. The power supply provides electrical energy to the drive motor, and the power supply can be a rechargeable battery, a disposable battery, or a power supply via a wire connected to a socket. The drive motor can be an electric motor, and the output shaft of the electric motor is mechanically connected to the reciprocating transmission mechanism. The reciprocating transmission mechanism converts the rotation of the output shaft into reciprocating linear motion, driving the transmission rod 10 and the penetration-enhancing unit 11 to reciprocate. Alternatively, the drive motor can also be an electromagnetic actuator, which controls the transmission rod 10 to drive the penetration-enhancing unit 11 to reciprocate through the reciprocating transmission mechanism. It is easy to understand that in some scenarios, the penetration-enhancing device 1 can also be a manually driven device. Similarly, the delivery device in this technical solution can also include a motor, a power supply, a switch, a reciprocating transmission mechanism, a transmission rod, etc. The delivery unit 21 is driven to reciprocate and touch the skin surface by manual or electric means.

[0052] In this technical solution, the permeation-enhancing unit 11 is directly assembled to the end of the transmission rod 10. It is easily understood that, to facilitate the assembly and replacement of the permeation-enhancing unit 11, the delivery unit may also have fixing components, supporting components, connecting parts 12, etc. The permeation-enhancing unit 11 can be assembled to the transmission rod 10 via connecting parts 12 of the type such as threads or snap-fits. The fixing components and supporting components contact the outer shell of the permeation-enhancing device 1, making the delivery unit assembly more secure and the reciprocating motion more stable. Similarly, the delivery unit 21 can also be directly assembled or detachably assembled to the delivery device in a similar manner.

[0053] The technical solution will be further illustrated below through several specific embodiments. Example 1

[0054] Figure 1 This is a flowchart of one embodiment of the drug-loaded desktop transdermal care system of the present invention. Figure 2 This is a schematic diagram of the permeation-enhancing device in Embodiment 1 of the drug-loaded tabletop transdermal care system of the present invention. Figure 3 This is a schematic diagram of the permeation enhancement unit in Embodiment 1 of the drug-loaded tabletop transdermal care system of the present invention. Figure 4 This is a schematic diagram of the delivery unit in Embodiment 1 of the drug-loaded tabletop transdermal care system of the present invention.

[0055] like Figure 2As shown, in this embodiment, the penetration-enhancing device 1 has a transmission rod 10, which is powered by a drive motor and can reciprocate along its own axis. The penetration-enhancing unit 11 has a connector 12, which is detachably mounted to the end of the transmission rod 10. When the penetration-enhancing unit 11 is driven by the transmission rod 10 to reciprocate in a straight line, it has an upper position and a lower position. The upper position refers to the position where the penetration-enhancing unit 11 moves to its limit towards the outside of the housing, and the lower position refers to the position where the penetration-enhancing unit 11 moves to its limit towards the inside of the housing. In some embodiments, when the penetration-enhancing unit 11 is in the lower position, the penetration-enhancing unit 11 is completely retracted into the port, that is, the penetration-enhancing unit 11 does not extend beyond the port. This design allows the user to easily slide and operate the penetration-enhancing device 1 when caring for the skin.

[0056] like Figure 2 and Figure 3 As shown, in this embodiment, the penetration-enhancing unit 11 includes a substrate 111 and penetration-enhancing microunits 112. The substrate 111 is made of materials such as monocrystalline silicon, metal, ceramic, or polymer. In some processing scenarios, the surface of the substrate 111 is treated by 3D etching, laser engraving, or wet etching processes to form the penetration-enhancing microunits 112 on the surface of the substrate 111. In this case, the material of the penetration-enhancing microunits 112 is monocrystalline silicon, metal, ceramic, or polymer. The penetration-enhancing unit 11 in this technical solution is the transdermal microneedle product in the field of transdermal drug delivery technology. Preferably, the penetration-enhancing unit 11 is a nanocrystal. When the penetration-enhancing unit 11 touches the skin, the penetration-enhancing microunits 112 can puncture the skin, weakening the barrier protection of the stratum corneum and improving the transdermal absorption efficiency of the active ingredients.

[0057] like Figure 3 As shown, in this embodiment, the permeation-enhancing microunit 112 is generally conical. Alternatively, the permeation-enhancing microunit 112 can also be prismatic, cylindrical, pyramidal, etc., with its ends processed to facilitate skin puncture. Figure 3 As shown, the end of the penetration-enhancing microunit 112 is conical. Alternatively, the penetration-enhancing microunit 112 can also be pyramidal or blade-shaped. In this embodiment, the end diameter of the penetration-enhancing microunit 112 is no greater than 200 nanometers, achieving a nanometer-level precision. Optionally, the end size is 80 nanometers, which is one-thousandth the diameter of a human hair, enabling painless and non-invasive efficient penetration-enhancing treatment of the skin. In this embodiment, the length of the penetration-enhancing microunit 112 is no greater than 3000 micrometers. In some products, the penetration-enhancing microunits 112 are arranged in a rectangular array, a circular array, or a honeycomb array on the substrate 111. Optionally, the penetration-enhancing microunits 112 are arranged in a square array on the substrate 111 in the manner of 8*8, 7*7, 6*6, 5*5, 4*4, or 3*3.

[0058] like Figures 1 to 3 As shown, in this embodiment, step s1 involves skin care, where the penetration-enhancing device 1 is used to repeatedly touch a specific area of ​​the skin, weakening the skin's stratum corneum barrier and enhancing its transdermal absorption capacity. Afterwards, a misting device is used to moisten the skin surface before step s2. It is easy to imagine that step s2 can involve various other methods of moisturizing, such as cleaning the skin with water, applying a wet compress, or spraying water on the skin, as long as a moist microenvironment is maintained. A moist microenvironment makes the skin tissue more conducive to the dissolution and absorption of active ingredients. It is also easy to understand that steps s1 and s2 can be performed simultaneously, or their order can be interchanged.

[0059] After completing steps s1 and s2, step s3 is performed: the delivery device is used to repeatedly touch the skin in a specific area to deliver the active ingredient. In step s3 of this embodiment, the delivery device includes a motor, power supply, switch, reciprocating transmission mechanism, transmission rod, and other structures. The delivery device electrically drives the delivery unit 21 to reciprocate and touch the skin surface.

[0060] like Figure 4 As shown, the delivery unit 21 has a drug-carrying platform 211. In this embodiment, the drug-carrying platform 211 has a planar drug-carrying surface 210. A drug coating 22 is coated on the drug-carrying surface 210. The drug coating 22 is solid and adhered to the drug-carrying surface 210. A drug coating 22 of a specific thickness or dosage can be applied to the drug-carrying surface 210 by spraying, dipping, dripping, dispensing, etc., and a specific process can be used to cure the drug coating 22. The drug coating 22 is soluble in water. In this embodiment, the drug coating 22 contains an active ingredient, which includes at least one of finasteride, minoxidil, GLP-1, insulin, smegglutinin, conotoxin, tranexamic acid, hexapeptide, salicylic acid, L-ascorbic acid, retinoic acid, and botulinum toxin. It is readily conceivable that in some embodiments, the drug coating 22 contains at least one of water, ethanol, hyaluronic acid, isopropanolamine, and isopropanol. When the delivery device moves the delivery unit 21 to touch the skin surface, the drug coating comes into contact with the water on the skin and partially dissolves, after which the drug penetrates into the deeper layers of the skin along with the water. When the number of touches reaches a certain number, the drug coating 22 is completely dissolved and absorbed. In some embodiments, when using this technical solution for scalp hair loss treatment, the content of finasteride in the active ingredient is not less than 0.01% and not more than 3%, and the content of minoxidil is not less than 0.01% and not more than 5%.

[0061] In step s3 of this embodiment, the vibration frequency of the delivery device is 1000-5000 times / minute. When using an electrically driven high-precision mechanical transmission system, the contact time between the drug coating 22 and the moisture on the skin surface is very short and fixed, resulting in a very small and uniform amount of drug coating 22 dissolving each time. During operation, the delivery device is moved to different areas of the skin for treatment, and a quantitative, trace amount of active ingredient is applied to the skin surface with each touch until the delivery unit 21 contacts the skin a sufficient number of times, at which point the drug coating slowly, evenly, and completely dissolves. In this embodiment, this specific number of touches is not less than 100 touches and not more than 50,000 touches; further, it is not less than 1000 touches and not more than 50,000 touches, such as 1000, 2000, 3000, 10000, 30000, 35000, 40000, 45000, etc.

[0062] In this first embodiment, the dissolution rate of the drug coating 22 can be precisely quantified and controlled by the specific number of touches required. Therefore, this technical solution allows for intuitive and convenient adjustment and control of the release and absorption of the active ingredients. Furthermore, the nursing procedure can be paused at any time. For example, when performing eye area skin care, the specific number of touches can be designed to be 1000, and the vibration frequency of the delivery device can be selected as 2000 times / minute. This means that the user can perform even and repeated massage care on the skin around the eyes within half a minute. Users can also perform longer care for specific areas of eye wrinkles according to their needs. In this embodiment, users can perform precise, targeted, and quantitative care of the skin, similar to an application, making the operation simple, intuitive, and controllable. When the user needs to pause the care, the drug coating 22 remains stably stored on the drug-carrying surface 210 of the delivery unit 21, and the active ingredients remaining in the drug coating remain active, preventing waste. When resuming the care, the active ingredients in the drug coating can be directly reused, making the overall operation more convenient. It's worth noting that because the residual active ingredients can immediately separate from the skin, no new active ingredients will come into contact with or be absorbed by the skin after the treatment is paused. This feature is especially important in cases of sudden reactions such as drug allergies, as it prevents the skin from being overstimulated or damaged by unsuitable active ingredients.

[0063] It is worth noting that the number of touches required for the complete dissolution of the drug coating 22 can be adjusted by changing parameters such as the thickness and dissolution difficulty of the drug coating 22. Example 2

[0064] Figure 5 This is a schematic diagram of the delivery unit in Embodiment 2 of the drug-carrying tabletop transdermal care system of the present invention. Figure 5As shown, unlike Embodiment 1, in Embodiment 2, the drug-carrying surface 210 of the drug-carrying platform 211 of the delivery unit 21 is provided with delivery micro-units 212. That is, the drug-carrying surface 210 is no longer a plane, but has a raised structure. A drug coating 22 is applied to the drug-carrying surface 210 and the delivery micro-units 212. In some embodiments, the delivery micro-units 212 can be micro-protrusions, micro-needles, or micro-blades. The drug coating 22 covering the delivery micro-units 212 can penetrate deeper into the skin. After contacting moisture in the skin, the drug coating 22 dissolves, and the active ingredient is efficiently absorbed by the skin. It is easily understood that in some other embodiments, the drug coating 22 may only cover the delivery micro-units 212 without contacting the drug-carrying surface 210. Specific processes can employ spraying, immersion, dripping, dispensing, etc. Example 3

[0065] Figure 6 This is a flowchart of Embodiment 3 of the drug-loaded desktop transdermal care system of the present invention. Figure 7 This is a schematic diagram of the permeation enhancement unit in Embodiment 3 of the drug-loaded transdermal care system of the present invention. Figure 6 and Figure 7 As shown, unlike Embodiment 2, Embodiment 3 provides a further simplified technical solution. In Embodiment 3, a penetration-enhancing unit 11 is used instead of a delivery unit 21, a drug-carrying surface 210 is formed on the surface of the substrate 111, a penetration-enhancing microunit 112 replaces a delivery microunit 212, and a drug coating 22 covers the surface of the substrate 111 and the penetration-enhancing microunit 112. That is, the penetration-enhancing unit 11 and the delivery unit 21 are combined into one.

[0066] Therefore, the operation of the drug-loaded transdermal care system in this embodiment includes the following steps: t1 moisturizing the skin in a specific area; t2 using the penetration-enhancing device to repeatedly touch the skin in the specific area. Each time the specific area of ​​skin is touched, the drug coating partially dissolves, and after a certain number of touches, the drug coating completely dissolves. The penetration-enhancing microunit 112 in this embodiment uses a solid microneedle body with sufficient structural strength to efficiently and stably puncture the skin. In this embodiment, steps s1 and s3 in the original embodiment 2 are combined. While the penetration-enhancing microunit 112 punctures the skin and weakens the skin barrier, the drug coating 22 directly contacts the deep layers of the skin, causing the drug coating 22 to dissolve and the active ingredients it carries to be efficiently absorbed by the skin. Using the care system in this embodiment, the user only needs to spray water on the face for moisturizing, and then operate the penetration-enhancing device to simultaneously complete the skin barrier weakening and active ingredient replenishment in one step, further simplifying the care system. Example 4

[0067] Figure 8This is a schematic diagram of the permeation enhancement unit in Embodiment 4 of the drug-loaded transdermal care system of the present invention. Figure 8 As shown, unlike Example 3, in this Example 4, the drug coating 22 may only cover the penetration-enhancing microunits 112 without contacting the surface of the substrate 111. Specific processes may include spraying, immersion, dripping, dispensing, etc. Example 5

[0068] Figure 9 This is a schematic diagram of the permeation enhancement unit in Embodiment 5 of the drug-loaded tabletop transdermal care system of the present invention. Figure 9 As shown, unlike Embodiments 3 and 4, in this Embodiment 5, each permeation-enhancing microunit 112 has multiple tips 113 formed at its end. These tips 113 are clustered together, and the gaps between the tips 113 form drug storage spaces. For example... Figure 9 As shown, in this fifth embodiment, the drug coating 22 is applied to the tip 113 and the drug storage space. The tip 113 can increase the surface area of ​​the permeation-enhancing microunit 112, thereby multiplying the adhesion area of ​​the drug coating 22 and enhancing the bonding force between the drug coating 22 and the permeation-enhancing microunit 112. At the same time, this structure can increase the drug loading capacity of the micro-protrusions, achieving high-dose drug delivery.

Claims

1. A drug-loaded table type transdermal nursing system comprising a penetration facilitating device, the penetration facilitating device comprising a penetration facilitating unit, the penetration facilitating unit having a substrate and penetration facilitating micro-units formed on the substrate; the penetration facilitating device being capable of weakening the skin barrier by multiple reciprocating touches on a specific area of the skin, characterized in that, further comprising a delivery device; the delivery device comprising a delivery unit, the delivery unit having a drug-loaded platform, a drug coating layer being provided on a drug-loaded surface of the drug-loaded platform, the drug coating layer being water-soluble and containing an active ingredient; the delivery device being capable of delivering the active ingredient by multiple reciprocating touches on the specific area of the skin, the drug coating layer being partially dissolved each time the specific area of the skin is touched, and the drug coating layer being completely dissolved when the number of touches reaches a specific number. The specific area comprises at least one of the head, face, eye area, neck, and hand.

2. The medicated table top transdermal nursing system according to claim 1, wherein, The penetration facilitating micro-units are made of at least one of single crystal silicon, ceramic, and polymer material.

3. The medicated table top transdermal nursing system according to claim 1, wherein, The end of the penetration facilitating micro-units is conical, pyramidal, or blade-shaped.

4. The medicated table top transdermal nursing system according to claim 3, wherein, The diameter of the end of the penetration facilitating micro-units is not greater than 200 nanometers.

5. The medicated table top transdermal nursing system according to claim 4, wherein, The active ingredient comprises at least one of finasteride, minoxidil, GLP-1, insulin, semaglutide, conotoxin, tranexamic acid, hexapeptide, salicylic acid, levovitamin C, tretinoin, and botulinum toxin.

6. The medicated table top transdermal nursing system of claim 1, wherein, The content of the finasteride is not less than 0.01% and not greater than 3%.

7. The medicated table top transdermal nursing system according to claim 6, wherein, The content of the minoxidil is not less than 0.01% and not greater than 5%.

8. The medicated table top transdermal nursing system according to claim 6, wherein, The drug-loaded surface is planar.

9. The medicated table top transdermal nursing system of claim 1, wherein, The drug-loaded surface has delivery micro-units, the drug coating layer covering the drug-loaded surface and the delivery micro-units, or the drug coating layer covering only the delivery micro-units.

10. The medicated table top transdermal nursing system of claim 1, wherein, The substrate surface forms the drug-loaded surface, the penetration facilitating micro-units replace the delivery micro-units, and the drug coating layer covers the drug-loaded surface and the penetration facilitating micro-units, or the drug coating layer covers only the penetration facilitating micro-units; 11. The medicated table top transdermal nursing system according to claim 10, wherein, The penetration facilitating device drives the penetration facilitating unit to touch the specific area of the skin multiple times reciprocally; The drug coating layer is partially dissolved each time the specific area of the skin is touched, and the drug coating layer is completely dissolved when the number of touches reaches a specific number. The end of the penetration facilitating micro-units has multiple tips, multiple tips combine to form a cluster, and the drug coating layer is arranged in multiple tips and gaps between tips.

12. The medicated table top transdermal nursing system according to claim 11, wherein, The specific number is not less than 100 times and not greater than 50,000 times.

13. The medicated table top transdermal nursing system according to any one of claims 1 to 12, characterized in that, ​

Images